![]() |
Name |
Abyssomycin Z
|
Molecular Formula | C29H34N2O11S | |
IUPAC Name* |
(2R)-2-[(3-hydroxypyridine-2-carbonyl)amino]-2-methyl-3-[[(1R,5S,7R,9R,14R,18S)-2,7,10-trihydroxy-7,9,16-trimethyl-6,12-dioxo-13,17-dioxapentacyclo[9.5.2.03,14.05,18.014,18]octadec-10-en-4-yl]sulfanyl]propanoic acid
|
|
SMILES |
C[C@@H]1C[C@@](C(=O)[C@H]2C(C3C([C@H]4C(C[C@]35[C@@]2(O4)C(=C1O)C(=O)O5)C)O)SC[C@@](C)(C(=O)O)NC(=O)C6=C(C=CC=N6)O)(C)O
|
|
InChI |
InChI=1S/C29H34N2O11S/c1-11-8-27(4,40)22(35)16-21(43-10-26(3,25(38)39)31-23(36)17-13(32)6-5-7-30-17)14-19(34)20-12(2)9-28(14)29(16,41-20)15(18(11)33)24(37)42-28/h5-7,11-12,14,16,19-21,32-34,40H,8-10H2,1-4H3,(H,31,36)(H,38,39)/t11-,12?,14?,16-,19?,20-,21?,26+,27-,28-,29-/m1/s1
|
|
InChIKey |
WOKGFSOGLPUSFC-FFODJPCZSA-N
|
|
Synonyms |
Abyssomycin Z
|
|
CAS | NA | |
PubChem CID | 156582642 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 618.7 | ALogp: | 1.0 |
HBD: | 6 | HBA: | 13 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 238.0 | Aromatic Rings: | 7 |
Heavy Atoms: | 43 | QED Weighted: | 0.247 |
Caco-2 Permeability: | -5.846 | MDCK Permeability: | 0.00000422 |
Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.969 |
Human Intestinal Absorption (HIA): | 0.134 | 20% Bioavailability (F20%): | 0.681 |
30% Bioavailability (F30%): | 0.087 |
Blood-Brain-Barrier Penetration (BBB): | 0.037 | Plasma Protein Binding (PPB): | 64.48% |
Volume Distribution (VD): | 0.312 | Fu: | 32.00% |
CYP1A2-inhibitor: | 0.001 | CYP1A2-substrate: | 0.151 |
CYP2C19-inhibitor: | 0.007 | CYP2C19-substrate: | 0.064 |
CYP2C9-inhibitor: | 0.002 | CYP2C9-substrate: | 0.278 |
CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.07 |
CYP3A4-inhibitor: | 0.026 | CYP3A4-substrate: | 0.09 |
Clearance (CL): | 3.217 | Half-life (T1/2): | 0.529 |
hERG Blockers: | 0.035 | Human Hepatotoxicity (H-HT): | 0.929 |
Drug-inuced Liver Injury (DILI): | 0.98 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.99 | Maximum Recommended Daily Dose: | 0.699 |
Skin Sensitization: | 0.043 | Carcinogencity: | 0.085 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.407 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004416 | ![]() |
0.345 | D0J2NK | ![]() |
0.263 | ||
ENC004417 | ![]() |
0.325 | D0S0LZ | ![]() |
0.258 | ||
ENC005072 | ![]() |
0.255 | D0T5XN | ![]() |
0.246 | ||
ENC002871 | ![]() |
0.252 | D04VEJ | ![]() |
0.242 | ||
ENC003816 | ![]() |
0.250 | D05AFR | ![]() |
0.237 | ||
ENC003851 | ![]() |
0.249 | D0H1AR | ![]() |
0.235 | ||
ENC003260 | ![]() |
0.248 | D08NQZ | ![]() |
0.235 | ||
ENC004310 | ![]() |
0.247 | D0C9XJ | ![]() |
0.233 | ||
ENC005546 | ![]() |
0.246 | D07VLY | ![]() |
0.233 | ||
ENC000710 | ![]() |
0.244 | D01XWG | ![]() |
0.230 |